Objective: To explore the expression of clec2 in patients with myelodysplastic syndrome (MDS) and to analyze its correlation with TPO.
Methods: The expression of plasma clec2 in 47 patients with MDS and 20 normal controls was detected by ELISA, and the correlation between the clinical characteristics of MDS patients and clec2 expression was analyzed. Meanwhile, the expression level of plasma TPO in 42 patients with MDS was detected, and its correlation with clec2 was analyzed.
Results: The expression of clec2 was 171.5.2±57.6 ng/ml in normal controls and 347.9±121.5 ng/ml in patients with MDS (P＜0.01). The expression level was 375.4±124.3 ng/ml in the initial treatment patients and 288.6±98.7 ng/ml in the re-treatment patients (P＜0.05). There was no relationship between clec2 and sex, age, number of peripheral blood cells, bone marrow blast cells. However, further analysis showed that there was a positive correlation between clec2 and TPO (r=0.419, P＜0.01).
Conclusion: Clec2 is highly expresses in MDS patients and positively correlates with TPO. The interaction between clec2 and TPO may play an important role in the occurrence and development of MDS, which may be the new molecular mechanism and mechanism of targeted therapy.
题目: Clec2在骨髓增生异常综合征患者中的表达及其与TPO的相关性.
目的: 探讨clec2在骨髓增生异常综合征（MDS）患者中的表达，并分析clec2与TPO的相关性.
方法: 应用ELISA方法检测47例MDS患者及20例正常人血浆中clec2的表达，分析MDS患者临床特征与clec2表达的相关性；同时检测42例MDS患者血浆TPO的表达水平，并分析clec2与TPO的相关性.
结果: Clec2在正常人中表达水平为171.5±57.6 ng/ml，在MDS患者中的表达水平为347.9±121.5 ng/ml（P＜0.01）。其中初治MDS患者clec2表达水平为375.4±124.3 ng/ml，复治患者的表达水平为288.6±98.7 ng/ml（P＜0.05）。Clec2与患者性别、年龄、外周血细胞数、骨髓原始细胞数均无相关性。进一步分析发现，clec2与TPO存在正相关关系（r=0.419）.
结论: Clec2在MDS患者中表达增高，且与TPO呈正相关，2者相互作用可能在MDS疾病的发生、发展中起着重要作用，其可能是该病的新的分子机制及靶向治疗机制.